Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to nutrient intake, stimulating insulin release and suppressing glucagon output. GLP-1 peptides exhibit promising therapeutic results in treating type 2 diab